Desmopressin

A synthetic V2-selective analog of vasopressin, FDA approved since 1978, that concentrates urine through renal aquaporin-2 trafficking and raises von Willebrand factor and factor VIII without the pressor activity of the parent hormone.

Also referenced as: DDAVP, dDAVP, Desmopressin Acetate, 1-deamino-8-D-arginine vasopressin, 1-desamino-8-D-arginine vasopressin, Minirin, Nocdurna, Noctiva, Stimate, Octostim

Also appears in: Cardiovascular

What is desmopressin?

Desmopressin is a synthetic nonapeptide analog of arginine vasopressin, formally 1-deamino-8-D-arginine vasopressin and universally abbreviated DDAVP. It differs from the parent hormone at exactly two positions: the free amino group at residue 1 is removed, leaving 3-mercaptopropionic acid where vasopressin has cysteine, and the L-arginine at residue 8 is replaced by its D-enantiomer. Those two edits are the whole drug — they lengthen the duration of action and remove nearly all of the vasoconstrictor activity while leaving the antidiuretic activity intact, which is what the approved labeling means when it describes “increased duration of action and a decreased vasopressor action.”

It reaches the research-peptide market for reasons that have little to do with consumer interest. Desmopressin is a standard laboratory reagent — the selective V2 agonist used in renal water-transport work and in von Willebrand factor release assays — and it is sold as a reference peptide in milligram quantities alongside vasopressin itself. It is also a named masking agent on the World Anti-Doping Agency Prohibited List, which gives it a second, separate reputation in performance circles.

How it works

Desmopressin acts almost entirely through the V2 vasopressin receptor, and the split between its two clinical effects is a split between two tissues that express the same receptor:

• Renal V2 receptors (antidiuresis) — Gs-coupled signaling in collecting duct principal cells raises cAMP and drives aquaporin-2 water channels into the apical membrane, increasing water permeability and concentrating urine (Nielsen et al., Proceedings of the National Academy of Sciences, 1995, 92(4):1013–1017)
• Endothelial V2 receptors (hemostasis) — the same cAMP pathway triggers exocytosis of Weibel-Palade bodies, releasing von Willebrand factor into plasma; factor VIII rises alongside it, though the mechanism behind the factor VIII response has never been fully worked out. The vWF effect is blocked by the selective V2 antagonist SR121463B and by protein kinase A inhibition, which is what established it as V2-mediated and endothelial rather than a direct platelet action (Kaufmann et al., Journal of Clinical Investigation, 2000, 106(1):107–116; Kaufmann & Vischer, Journal of Thrombosis and Haemostasis, 2003, 1(4):682–689)
• Near-absent V1a activity — the D-arginine substitution at position 8 is what removes the pressor effect. Manning and colleagues re-measured the analog’s potencies and put dDAVP at 1,200 ± 126 units/mg of antidiuretic activity against 0.39 ± 0.02 units/mg of vasopressor activity, an antidiuretic-to-pressor ratio of 3,000 — a ratio the authors noted was far higher than the values originally reported for the compound (Manning et al., Journal of Medicinal Chemistry, 1976, 19(6):842–845)
• Residual V1b/V3 activity at pituitary corticotrophs — desmopressin is not perfectly V2-selective. The V3 (V1b) receptor is part of the corticotroph phenotype, expressed in 17 of 18 ACTH-secreting pituitary adenomas tested and in the bronchial carcinoids responsible for ectopic ACTH syndrome, and that residual agonism is the basis of the desmopressin stimulation test still used in the workup of Cushing syndrome (de Keyzer et al., Journal of Clinical Investigation, 1996, 97(5):1311–1318)

The contrast with vasopressin is the point of the molecule: the parent hormone signals through V1a, V1b, and V2 and is used clinically as a vasopressor, while its analog was engineered to keep only the V2 arm.

Research status

Desmopressin has one of the longest approval records of any peptide PeptideBenchmark tracks, and a correspondingly mature — and in places negative — evidence base.

Origin and approval. The Prague group that synthesized the analog reported the first human data in patients with diabetes insipidus in 1968 (Vávra et al., Lancet, 1968, 1(7549):948–952). The FDA approved desmopressin in 1978 for diabetes insipidus and bleeding disorders (Fralick et al., PLoS Medicine, 2019, 16(10):e1002930). Current U.S. labeling splits by formulation: DDAVP Injection is indicated for central diabetes insipidus, hemophilia A with factor VIII activity above 5%, and type I von Willebrand disease with factor VIII activity above 5%; DDAVP Tablets are indicated for central diabetes insipidus and for primary nocturnal enuresis.

Hemostasis. The hemostatic use was discovered rather than designed. Mannucci et al. (1977) reported that DDAVP infusion raised factor VIII coagulant activity two- to threefold at 0.3 mcg/kg, and four- to sixfold at higher doses in patients whose starting activity was 9% or above, carrying eight patients with mild hemophilia or von Willebrand disease through dental extraction and major surgery — cholecystectomy, thoracotomy, two tonsillectomies — without plasma concentrate. The result was not uniform: two of the four patients given the lower dose before dental surgery still needed concentrate to control oozing from the sockets (Lancet, 1(8017):869–872). The same group later showed it shortened the bleeding time in uremia in a randomized double-blind crossover trial of 12 patients (New England Journal of Medicine, 1983, 308(1):8–12). These two indications remain the best-supported non-renal uses.

Surgical bleeding — largely negative. The Cochrane review of desmopressin for perioperative transfusion identified 65 completed trials and 3,874 participants, and found it probably makes little or no difference to the number of patients transfused (RR 0.96, 95% CI 0.86 to 1.06; 25 trials, 1,806 participants; moderate-quality evidence). Heterogeneity between surgical settings was large enough that the volume and blood-loss outcomes were reported by subgroup rather than pooled: desmopressin may slightly reduce transfused red cell volume in adult cardiac surgery (mean difference −0.52 units; 14 trials, 957 participants) but not in orthopedic, vascular, or hepatic surgery, and compared with tranexamic acid it may increase blood loss (Desborough et al., Cochrane Database of Systematic Reviews, 2017, 7(7):CD001884). A multicenter randomized trial in patients actively bleeding after cardiac surgery who had already received tranexamic acid was stopped early for futility: 54% of the desmopressin arm versus 49% of placebo required red cell transfusion (P = 0.34), with no difference in blood loss, ventilation, ICU stay, or mortality (Bignami et al., Acta Anaesthesiologica Scandinavica, 2016, 60(7):892–900).

Nocturnal enuresis — effective during treatment, not after. The Cochrane review covering 41 randomized trials in 2,760 children found desmopressin reduced bedwetting by at least one night per week versus placebo during treatment, but found no difference once treatment stopped, and concluded that alarm-based interventions may produce more sustained benefit (Glazener & Evans, Cochrane Database of Systematic Reviews, 2002, (3):CD002112).

Nocturia. Two multicenter randomized placebo-controlled trials of low-dose orally disintegrating desmopressin, run separately in women and in men because the effective dose differs by sex, supported a sublingual nocturia indication (Sand et al., Journal of Urology, 2013, 190(3):958–964; Weiss et al., Journal of Urology, 2013, 190(3):965–972). Nocdurna, the sublingual tablet those trials supported, was approved in 2018; a separate nasal-spray program produced Noctiva in 2017. Both carried boxed warnings for hyponatremia, and both have since been withdrawn from the U.S. market — neither appears in DailyMed’s current listings. The regulatory approval was real; the commercial and clinical uptake was not.

Antiplatelet-associated traumatic intracranial hemorrhage — unresolved. A 2026 systematic review of off-label desmopressin for platelet-function reversal screened 57 records and found only three retrospective cohorts (5,841 patients) eligible, with heterogeneity in design, dosing, timing, and outcome definitions that ruled out a meta-analysis. A radiographic signal appeared in mild traumatic brain injury (adjusted OR ≈ 0.26 for hematoma expansion), but there was no mortality benefit and no consistent functional improvement; the authors called for TBI-specific randomized trials (Dawoud et al., Clinical Neurology and Neurosurgery, 2026, 266:109400).

Active work. ClinicalTrials.gov currently lists nine active, recruiting, or not-yet-recruiting interventional studies, concentrated in Cushing syndrome diagnostics, pediatric enuresis, kidney-biopsy and cardiac-surgery bleeding, and hyponatremia prevention. There is no active program in anti-aging, cognition, or performance indications.

Common dosage forms

• Tablets — 0.1 mg and 0.2 mg scored oral tablets, supplied by a long list of generic labelers and the mainstay of outpatient oral dosing.
• Injection — sterile aqueous solution at 4 mcg/mL in single-dose ampules and multiple-dose vials for intravenous or subcutaneous use. A 15 mcg/mL concentration is marketed outside the U.S. under a separate brand.
• Nasal spray — 10 mcg per 0.1 mL metered spray (0.1 mg/mL) for antidiuretic use, and a separate 1.5 mg/mL spray delivering 150 mcg per actuation for bleeding disorders. There is also a rhinal tube solution at 0.1 mg/mL for volumes the spray pump cannot deliver.
• Sublingual lyophilisate and oral solution — fast-dissolving “melt” tablets in microgram strengths and a ready-made oral solution; the U.S. sublingual nocturia product has been discontinued, though a branded oral solution remains marketed.
• Research supply — lyophilized desmopressin acetate powder in milligram quantities, sold as an analytical reference peptide or V2-agonist assay reagent. Bulk drug substance listings from peptide manufacturers also appear in DailyMed.

Note the units. Approved desmopressin products are dosed in micrograms while research-peptide vials are conventionally labeled in milligrams — a thousandfold difference in the numbers printed on a label.

Key considerations

• The approvals are narrow and formulation-specific. Desmopressin is approved for central diabetes insipidus, primary nocturnal enuresis, hemophilia A, and type I von Willebrand disease, with indications that differ between the tablet, injection, and nasal forms. No desmopressin product carrying a nocturia indication is currently marketed in the U.S. Nothing in that record extends to anti-aging, cognitive, athletic, or general wellness framing.
• Hyponatremia is the dominant safety signal, and it is quantified. DDAVP Injection carries a boxed warning stating that severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death; both discontinued nocturia products carried the same warning. In a propensity-matched cohort of 3,137 new desmopressin users matched to 3,137 new oxybutynin users, the hyponatremia rate was 146 per 1,000 person-years versus 11 per 1,000 — a roughly 13-fold higher rate (HR 13.19; 95% CI 6.69–26.01) (Fralick et al., PLoS Medicine, 2019, 16(10):e1002930). The Cochrane enuresis review advised limiting fluid intake during treatment specifically because of water intoxication risk.
• It is a banned substance in sport, at all times. Desmopressin is named explicitly under S5 (Diuretics and Masking Agents) of the WADA Prohibited List as a masking agent, and S5 substances are prohibited both in and out of competition. Validated detection methods have been published for doping-control use in urine (Thomas et al., Analytica Chimica Acta, 2011, 707(1–2):107–113; Esposito et al., Biomedical Chromatography, 2013, 27(2):240–245) and in plasma (Esposito et al., Analytical and Bioanalytical Chemistry, 2012, 402(9):2789–2796).
• Potency errors have happened at manufacturing scale. In 2020 Ferring voluntarily recalled all marketed lots of DDAVP Nasal Spray, generic desmopressin acetate nasal spray, and Stimate nasal spray for superpotency, traced to a defect in the tightness of the bottle seal; the FDA classified it as a Class I recall. When a licensed manufacturer can ship out-of-specification microgram doses, unlabeled or uncharacterized material warrants more caution, not less.
• Naming and concentration confusions are dense. Desmopressin is not vasopressin (AVP/ADH, a V1a/V1b/V2 agonist used as a vasopressor), not terlipressin, and not lypressin. “DDAVP” serves as both the generic abbreviation and a U.S. brand name. Most consequentially, the two nasal sprays differ fifteenfold in concentration — 0.1 mg/mL for the antidiuretic product versus 1.5 mg/mL for the bleeding-disorder product — and are not interchangeable. Labeling also warns that use in type IIB von Willebrand disease may cause platelet aggregation and thrombocytopenia.